Author:
Raber-Durlacher Judith E.,Treister Nathaniel S.,Zadik Yehuda,Dean David R.,Miranda-Silva Wanessa,Fregnani Eduardo R.,Epstein Joel B.,Elad Sharon
Abstract
Abstract
Purpose
A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS is focused on the risk of secondary oral cancer following hematopoietic cell transplantation (HCT).
Methods
This CPS was developed based on critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. The information is presented in the form of succinct bullets to generate a short manual about the best standard of care.
Results
Studies described a 7–16-fold higher risk of secondary oral cancer (mainly squamous cell carcinoma) in allogeneic HCT (alloHCT) recipients, particularly in those who developed chronic graft versus host disease (cGVHD). Risk increases over time and is influenced by several risk factors. In autologous HCT, oral cancer risk seemed only slightly elevated.
Conclusion
Clinicians should be aware of the higher oral cancer risk in alloHCT survivors, and emphasize the importance of lifelong oral cancer surveillance (at least every 6–12 months) and avoiding cancer promoting lifestyle factors in an empathic way, particularly of those with (a history of) cGVHD. Post-HCT for Fanconi anemia or dyskeratosis congenita, education and rigorous follow-up is even more crucial. In case of suspected oral lesions in the presence of oral mucosal cGVHD, a GVHD intervention may facilitate diagnosis. Suspected lesions should be biopsied. More research is needed on the role of HPV in oral cancer post-HCT.
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S et al (2021) Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 56(7):1651–64
2. Center for International Blood & Marrow Transplant Research. 2022 Annual Report 2022 [Available from: https://cibmtr.org/Files/Administrative-Reports/Annual-Reports/2022-Annual-Report-PRINT.pdf. Accessed Jul 2024
3. Janowiak-Majeranowska A, Osowski J, Mikaszewski B, Majeranowski A (2022) Secondary oral cancer after systemic treatment of hematological malignancies and oral GVHD: a systematic review. Cancers (Basel) 14(9):2175
4. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al (1997) Solid cancers after bone marrow transplantation. N Engl J Med. 336(13):897–904
5. Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al (2009) Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 113(5):1175–83
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献